With approval of generic MS drug, Mylan stock surges

With the approval from the U.S. Food and Drug Administration of a generic injection to treat multiple sclerosis, Mylan's shares rose 18 percent Wednesday afternoon. Mylan (NASDAQ: MYL), which is based in The Netherlands but run out of its corporate offices in Cannonsburg, received approval late Tuesday for its Glatiramer Acetate injection. The drug was approved by the government agency as a suitable generic version of Teva's (NYSE:TEVA) Copaxone to treat pati ents with relapsing forms of MS, according…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news